Sorafenib, commonly used in clinical dosage form as tablets, with the generic name of sorafenib mesylate tablets, is an antitumor drug and should be used in accordance with medical advice. This drug is an inhibitor of various kinases, which can inhibit the proliferation of tumor cells and anti-angiogenesis, and is mostly used for the treatment of inoperable advanced renal cell carcinoma, inoperable or distant metastatic hepatocellular carcinoma, as well as locally recurrent or metastatic radioactive iodine-refractory differentiated thyroid cancer. It should be noted that the use of the drug is prohibited for those who are allergic to any component of the drug, those who have a history of serious adverse reactions, pregnant women, nursing mothers, and the combined use of the drug should be in accordance with the doctor’s instructions. Some patients may experience headache, hypertension, diarrhea, nausea, rash, itching, anorexia, arthralgia, fatigue and other adverse reactions during the use of the drug, if more serious, should consult a doctor in time. The drug should be used in accordance with the doctor’s advice, not blindly use the drug by oneself, in order to avoid affecting the condition, or serious side effects.